Evommune (EVMN) Current Assets (2024 - 2026)

Evommune's (EVMN) quarterly Current Assets came in at $215.9 million in Q1 2026, up 40.64% on a QoQ basis from $153.5 million in Q4 2025.

Evommune (EVMN) Current Assets (2024 - 2026) Analysis & Trends

Evommune (EVMN) has 3 years of Current Assets data on file, last reported at $215.9 million in Q1 2026.

On a quarterly basis, Current Assets changed N/A year-over-year to $215.9 million in Q1 2026; TTM through Mar 2026 was $215.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at $153.5 million, up 107.44% from the prior year.
Current Assets for Q1 2026 stood at $215.9 million, up from $153.5 million in the prior quarter.
Over the last five years, Current Assets for EVMN reached as high as $215.9 million in Q1 2026 and fell as low as $74.0 million in Q4 2024.
Historically, Current Assets has averaged $131.3 million across 3 years, with a median of $117.7 million in 2025.
On a YoY basis, Current Assets climbed as much as 107.44% in 2025 and fell as far as 107.44% in 2025.
Year by year, Current Assets stood at $74.0 million in 2024, then surged by 107.44% to $153.5 million in 2025, then soared by 40.64% to $215.9 million in 2026.
Per Business Quant data, the three most recent Current Assets figures were $215.9 million in Q1 2026, $153.5 million in Q4 2025, and $81.9 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Assets (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	289.93 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	73.04 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	6.60 Bn
4	NuCana	279.75 Bn	279.75 Bn	-	35.73 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	11.73 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	18.21 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	521.86 Mn
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	8.07 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	1.97 Bn
10	Evommune	381.48 Mn	170.02 Mn	-	215.86 Mn

Download Data